New research reveals that people who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass far faster than those who halt conventional lifestyle plans.
Published data in a prominent health publication shows that while obese individuals frequently drop a large proportion of their body weight while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Users buying these medications must be cognizant of the danger of fast weight regain when the medication concludes," cautioned researcher Dr. Susan Jebb.
This pace of regain implies a return to starting mass in about a year and a half.
Weighing Therapies
The research, which examined dozens of studies involving thousands of participants, compared the effects of GLP-1 agonists with other pills.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone generally experience a more gradual weight regain—approximately 0.1 kg a month—post-intervention.
Explaining the Rapid Rebound
Nutrition scientists suggest the mechanism of the jabs accounts for the amplified weight return.
The injections imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the body to produce less of its endogenous GLP-1, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' means hunger is uncontrolled, making excessive eating a significant risk."
A Lifelong Disease?
Health authorities recommend the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.
A number of clinicians say that, given the significant potential of weight regain, the therapy might need to be life-long.
This view is supported by drug manufacturers, who note that the findings "emphasize the chronic nature of excess weight," comparing it to managing conditions like diabetes.
Patient Accounts
Individuals who have stopped the medication report a powerful resurgence of appetite.
"I experienced something flipping and you're instantly extremely hungry," described one woman.
This challenge is worsened if users have not adopted permanent lifestyle or habit changes during treatment.
Growing Use
Survey data suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is more common among women than males.
- The middle-aged age group shows the highest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while the jabs are potent agents for shedding pounds, they are not a standalone cure and maintained weight loss likely depends on ongoing behavioural support.